Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073216 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT00073216 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 96 participants.
The verdict
NCT00073216, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also test the safety of and immune response to a protein vaccine given alone.
Interventions
- BIOLOGICAL Clade B gag DNA/PLG and env DNA/PLG Microparticles
- BIOLOGICAL Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073216
The ClinicalTrials.gov registry entry for NCT00073216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clade B gag DNA/PLG and env DNA/PLG Microparticles is the first listed.
NCT00073216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073216 about?
NCT00073216 is a clinical study titled "Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults". To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also ...
What is the current status of trial NCT00073216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00073216?
The interventions under investigation include: Clade B gag DNA/PLG and env DNA/PLG Microparticles (BIOLOGICAL), Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00073216?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.